# Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

> **NCT01183676** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DEPAKOTE® Tablets, 500 MG
- **DRUG:** DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG

## Key facts

- **NCT ID:** NCT01183676
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2010-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01183676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01183676, "Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01183676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*